[go: up one dir, main page]

NO20062357L - Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer - Google Patents

Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer

Info

Publication number
NO20062357L
NO20062357L NO20062357A NO20062357A NO20062357L NO 20062357 L NO20062357 L NO 20062357L NO 20062357 A NO20062357 A NO 20062357A NO 20062357 A NO20062357 A NO 20062357A NO 20062357 L NO20062357 L NO 20062357L
Authority
NO
Norway
Prior art keywords
disease states
cancer
treatment
indoline derivatives
derivatives
Prior art date
Application number
NO20062357A
Other languages
English (en)
Inventor
Monica J Kochanny
Imadul Islam
Wheeseong Lee
Judi Bryant
Richard Feldman
Shendong Yuan
Damian Arnaiz
Yuo-Ling Chou
Paul Hrvatin
Mark Polokoff
Hongyi Yu
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20062357L publication Critical patent/NO20062357L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Indolinonderivater, så som forbindelser med formel (I) hvor A, m, n, R1, R2, R3, R5 og R6 er som beskrevet i beskrivelsen, er anvendelige til behandling av pattedyr med sykdomstilstander som kan lindres ved inhibering av PKD-1-aktivitet.
NO20062357A 2003-10-24 2006-05-23 Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer NO20062357L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51408103P 2003-10-24 2003-10-24
PCT/US2004/035262 WO2005040116A2 (en) 2003-10-24 2004-10-22 Indolinone derivatives and their use in treating disease-states such as cancer

Publications (1)

Publication Number Publication Date
NO20062357L true NO20062357L (no) 2006-07-14

Family

ID=34520168

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062357A NO20062357L (no) 2003-10-24 2006-05-23 Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer

Country Status (14)

Country Link
US (1) US7105563B2 (no)
EP (1) EP1680401A2 (no)
JP (1) JP2007509173A (no)
KR (1) KR20060123184A (no)
CN (1) CN1898205A (no)
AU (1) AU2004284084A1 (no)
BR (1) BRPI0415773A (no)
CA (1) CA2541460A1 (no)
IL (1) IL174788A0 (no)
MX (1) MXPA06004438A (no)
NO (1) NO20062357L (no)
RU (1) RU2006117635A (no)
WO (1) WO2005040116A2 (no)
ZA (1) ZA200604149B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10334582A1 (de) * 2003-07-28 2005-02-24 Basf Ag Verfahren zur Herstellung von Maleinsäureanhydrid
MXPA06006050A (es) * 2003-11-26 2007-05-24 Scripps Research Inst Inhibidores de proteina quinasa a base de indolinona.
DE102005015005A1 (de) * 2005-04-01 2006-10-05 Qiagen Gmbh Verfahren zur Behandlung einer Biomoleküle enthaltenden Probe
EP2016049A1 (en) * 2006-04-24 2009-01-21 Boehringer Ingelheim International GmbH 3- (aminomethyliden) 2-indolinone derivatives and their use as cell proliferation inhibitors
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
CA2662902C (en) * 2006-09-15 2015-11-24 Xcovery, Inc. Kinase inhibitor compounds
WO2009030270A1 (en) * 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
CA2736177A1 (en) 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
WO2009105504A2 (en) 2008-02-21 2009-08-27 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
EP2626361B1 (en) * 2008-04-24 2014-10-15 F2G Limited Pyrrole antifungal agents
CA2729745A1 (en) * 2008-06-30 2010-01-07 Cylene Pharmaceuticals, Inc. Oxindole compounds
CA2729253A1 (en) * 2008-07-02 2010-01-07 Generics [Uk] Limited Novel process
CN101397295B (zh) * 2008-11-12 2012-04-25 深圳微芯生物科技有限责任公司 作为组蛋白去乙酰化酶抑制剂的2-吲哚满酮衍生物、其制法和用途
EP2246326A1 (de) 2009-05-02 2010-11-03 Bayer CropScience AG Verfahren zur Herstellung von Oxindolen und ortho-substituierten Anilinen und ihre Verwendung als Zwischenprodukte für Synthesen
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX353257B (es) 2009-10-06 2018-01-05 Millennium Pharmaceuticals Inc Star Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
CN102283826A (zh) * 2010-06-21 2011-12-21 中国医学科学院基础医学研究所 维甲酸及其类似物用于治疗tsc1/tsc2失活或其上游通路活化导致的肿瘤
GB201014374D0 (en) * 2010-08-27 2010-10-13 Univ Greenwich Novel hybrid compounds
WO2012028162A1 (de) 2010-09-01 2012-03-08 Bayer Cropscience Ag Verfahren zur herstellung von oxindolen und ortho-substituierten anilinen und ihre verwendung als zwischenprodukte für synthesen
WO2012058780A1 (en) 2010-11-01 2012-05-10 Scinopharm (Kunshan) Biochemical Technology Co., Ltd. Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
CN102688234B (zh) * 2011-03-21 2015-07-29 华东理工大学 吲哚酮衍生物作为rsk2抑制剂的合成与应用
IN2014MN02105A (no) 2012-04-20 2015-09-11 Annji Pharm Co Ltd
JP6378308B2 (ja) * 2013-03-13 2018-08-22 ボストン バイオメディカル， インコーポレイテッド がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての３−（アリールまたはヘテロアリール）メチレンインドリン−２−オン誘導体
CN104211632B (zh) * 2013-05-31 2016-12-28 中国人民解放军军事医学科学院放射与辐射医学研究所 具有酪氨酸激酶抑制活性的2‑吲哚酮衍生物及其制备方法与应用
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
WO2016055454A1 (en) * 2014-10-06 2016-04-14 International Society For Drug Development S.R.L. Pharmaceutical combination for the treatment of tumors
EP3221308B1 (en) 2014-11-21 2018-09-19 F2G Limited Antifungal agents
EP3325100A4 (en) 2015-07-17 2019-02-20 Memorial Sloan-Kettering Cancer Center COMBINATION THERAPY WITH PDK1 AND PI3K INHIBITORS
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5854206A (en) * 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
IL139934A0 (en) 1998-05-29 2002-02-10 Sugen Inc Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
CA2354852C (en) 1998-12-17 2008-09-23 F. Hoffmann-La Roche Ag 4,5-azolo-oxindoles
DE69938258T2 (de) 1998-12-17 2009-02-26 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindole als proteinkinasehemmer
CN1136217C (zh) 1998-12-17 2004-01-28 霍夫曼-拉罗奇有限公司 作为jnk蛋白质激酶抑制剂的4-芳基羟吲哚
CN1147486C (zh) 1998-12-17 2004-04-28 霍夫曼-拉罗奇有限公司 4-和5-炔基羟吲哚和4-和5-烯基羟吲哚
EP1165513A1 (en) 1999-03-24 2002-01-02 Sugen, Inc. Indolinone compounds as kinase inhibitors
EP1259234B9 (en) * 1999-12-30 2007-02-14 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
MXPA02010759A (es) 2000-05-02 2004-07-30 Sugen Inc Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa.
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2003022815A1 (en) 2001-09-10 2003-03-20 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
JP2005508953A (ja) 2001-10-10 2005-04-07 スージェン・インコーポレーテッド キナーゼ阻害剤としての３−［４−（置換ヘテロサイクリル）−ピロール−２−イルメチリデン］−２−インドリノン誘導体
US20030119839A1 (en) * 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
PL208283B1 (pl) 2001-12-27 2011-04-29 Theravance Pochodna indolinonu, sposób jej wytwarzania, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca i zastosowanie tej kompozycji
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
PL377795A1 (pl) 2002-11-28 2006-02-20 Schering Aktiengesellschaft Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych
US20040266843A1 (en) * 2003-03-07 2004-12-30 Sugen, Inc. Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
ATE446951T1 (de) * 2003-06-10 2009-11-15 Biondi Ricardo Miguel Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung

Also Published As

Publication number Publication date
KR20060123184A (ko) 2006-12-01
CA2541460A1 (en) 2005-05-06
MXPA06004438A (es) 2006-06-20
RU2006117635A (ru) 2007-12-10
AU2004284084A1 (en) 2005-05-06
US20050090541A1 (en) 2005-04-28
ZA200604149B (en) 2007-11-28
BRPI0415773A (pt) 2006-12-26
IL174788A0 (en) 2006-08-20
WO2005040116A2 (en) 2005-05-06
US7105563B2 (en) 2006-09-12
JP2007509173A (ja) 2007-04-12
CN1898205A (zh) 2007-01-17
EP1680401A2 (en) 2006-07-19
WO2005040116A3 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
NO20062357L (no) Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer
NO20081217L (no) Nye benzotiazolonderivater
NO20061194L (no) Mitotiske kinesininbibitorer
NO20062583L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
TW200637820A (en) Indoles useful in the treatment of inflammation
NO20054407L (no) Cannabinoid reseptor ligander og deres anvendelser
HK1121440A1 (en) Biphenyl derivatives and their use in treating hepatitis c
EA200801108A1 (ru) Триазолы, пригодные для лечения воспалений
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
TW200745004A (en) Novel compounds, their preparation and use
NO20061363L (no) Pyrazolo- og imidazo- pyrimidinderivater
NO20081349L (no) Pyrrolopyrimidinderivater som Syk-inhibitorer
NO20071534L (no) Behandling av inflammatoriske forstyrrelser og smerte
NO20074274L (no) Tetrahydroindolon og tetrahydroindazolonderivater
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
NO20073099L (no) Amino-imidazoloner for inhibering av beta-sekretase
TW200637818A (en) Indoles useful in the treatment of inflammation
UY29617A1 (es) Compuestos químicos vii
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
EA200401124A1 (ru) Аминозамещённые (e)-2,6-диалкоксистирил-4-замещённые-бензилсульфоны для лечения пролиферативных расстройств

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application